Pfizer begins study of mRNA flu vaccine

09/27/2021 | 04:36pm

Sept 27 (Reuters) - Pfizer Inc said on Monday it had dosed the first patient in a trial testing a flu vaccine based on messenger RNA, the same technology used in the COVID-19 shots made by the U.S. drugmaker and BioNTech. (Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)

© Reuters 2021
Copier lien
Latest news about "Economy & Forex"
19m ago
24m ago
24m ago
46m ago
53m ago